drugset / Trial / NCT07053917
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
Phase 1
Recruiting
20 enrolled
Johns Hopkins University
Rose Hill · collabUniversity of California, Berkeley · collabUsona Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.
Timeline
- Start
- 2026-02-09
- Primary completion
- 2027-02
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 12.5 mg | — |
| Subject | Psilocybin | Other / unclassified | 25 mg | — |